Predictive modeling and heterogeneity of baseline risk in meta-analysis of individual patient data

被引:37
作者
Trikalinos, TA
Ioannidis, JPA [1 ]
机构
[1] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin Trials & Evidence Based Med Unit, GR-45110 Ioannina, Greece
[2] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA
关键词
meta-analysis; meta-analysis of individual patient data; randomized trials; heterogeneity; baseline risk; predictive models;
D O I
10.1016/S0895-4356(00)00311-5
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
We developed and evaluated methods for the analysis and interpretation of the baseline risk heterogeneity in meta-analysis of individual patient data (MIPD) based on information on predictive factors. We used data from a typical MIPD of eight clinical trials (1792 patients, 2947 years of follow-up) on the efficacy of high-dose acyclovir in human immunodeficiency virus infection. Cox models with four predictive factors (age, disease state, CD4 cell count and hemoglobin levels) were used to estimate predicted individual hazards both far single trials and for various MIPD modeling methods (simple pooling, adjusted for study, stratified per study, fixed and random effects for predictors). For each study and for each method of MIPD synthesis, we estimated the odds ratio for death in the upper versus the lower quartile of predicted risk (Extreme Quartile Odds Ratio, EQuOR) and the respective rate ratio (Extreme Quartile Rate Ratio, EQuRR). Only the CD4 cell count showed a significantly heterogeneous predictive effect across the eight studies (P = .024). The EQuOR of single studies ranged from 3.5 (little heterogeneity) to 24 (intermediate heterogeneity), substantially lower than the EQuOR of the MIPD (167 to 275, depending on the model used). The EQuRR values ranged from 3.5 to 77 for single studies and from 77 to 116 for the various MIPD models. Predictive modeling can be a major strength of MIPD, when performed and interpreted with standardized approaches. All models consistently show that MIPD may be a study design with extreme heterogeneity of patient baseline risk. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:245 / 252
页数:8
相关论文
共 19 条
[1]   GENERALIZING THE RESULTS OF RANDOMIZED CLINICAL-TRIALS [J].
BAILEY, KR .
CONTROLLED CLINICAL TRIALS, 1994, 15 (01) :15-23
[2]  
COX DR, 1972, J R STAT SOC B, V34, P187
[3]  
Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202
[4]   AN EVIDENCE BASED APPROACH TO INDIVIDUALIZING TREATMENT [J].
GLASZIOU, PP ;
IRWIG, LM .
BMJ-BRITISH MEDICAL JOURNAL, 1995, 311 (7016) :1356-1359
[5]   Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: A meta-analysis of randomized individual patient data [J].
Ioannidis, JPA ;
Collier, AC ;
Cooper, DA ;
Corey, L ;
Fiddian, AP ;
Gazzard, BG ;
Griffiths, PD ;
Contopoulos-Ioannidis, DG ;
Lau, J ;
Pavia, AT ;
Saag, MS ;
Spruance, SL ;
Youle, MS .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (02) :349-359
[6]  
Ioannidis JPA, 1998, AM J EPIDEMIOL, V148, P1117
[7]   Uncontrolled pearls, controlled evidence, meta-analysis and the individual patient [J].
Ioannidis, JPA ;
Lau, J .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (08) :709-711
[8]   Recursive cumulative meta-analysis: A diagnostic for the evolution of total randomized evidence from group and individual patient data [J].
Ioannidis, JPA ;
Contopoulos-Ioannidis, DG ;
Lau, J .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1999, 52 (04) :281-291
[9]   A COMPARISON OF METAANALYTIC RESULTS USING LITERATURE VS INDIVIDUAL PATIENT DATA - PATERNAL CELL IMMUNIZATION FOR RECURRENT MISCARRIAGE [J].
JENG, GT ;
SCOTT, JR ;
BURMEISTER, LF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (10) :830-836
[10]   Summing up evidence: one answer is not always enough [J].
Lau, J ;
Ioannidis, JPA ;
Schmid, CH .
LANCET, 1998, 351 (9096) :123-127